Poordad F, et al. - The researchers aimed to investigate the efficacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P) in patients with hepatitis C virus (HCV) Genotype 1 or 4 and prior direct-acting antiviral treatment failure. A high sustained virologic response at 12 weeks post-treatment (SVR12) rate was achieved by 16 weeks of G/P treatment among patients with HCV GT1 infection and prior failure to regimens containing either NS5A inhibitors or NS3 protease inhibitors.